- National median: $137,480/yr (BLS OES May 2024, SOC 29-1051 — Pharmacists). P25–P75: $127,250–$158,620; mean $137,210; top 10% exceed $172,040. 328,870 employed.
- Setting drives the spread: retail chain (CVS/Walgreens) historically led but has compressed via 2023–2025 hour cuts and store closures; hospital pays mid-band with stronger benefits/pension; clinical (oncology/ID/ambulatory care) leads at senior level with PGY-1/PGY-2; industry (pharma/PBM) sits at the high end.
- PharmD ROI has degraded: $200K+ all-in cost (4-yr program × $35–60K + 4 yrs foregone earnings) vs national median above; payback now 12–18 years post-grad in most retail-only paths — substantially worse than pre-2020 baseline.
- Real wage leaders: SD ($159,038 real), AK ($157,991), MN ($157,281). Nominal leaders CA/AK pay $165,150/$163,200 (rural undersupply premium + west-coast metro density).
- Specialty boards (BCPS, BCOP, BCACP) remain real differentiators — pull pay above BLS median in clinical and hospital roles even in saturated retail markets.
Where the spread is.
The same job, fifty-one wages.
Sorted by real P50 descending. Real wage is the BLS nominal P50 divided by the state's BEA RPP — the dollar that buys the same basket as the national average. Each row links to the full state page.
| Rank | ST | State | Real P50 | Nom. P50 | Distribution P10–P90 | RPP | Emp |
|---|---|---|---|---|---|---|---|
| 01 | SD | South Dakota | $159,038▲13% | $140,190 | 88.1 | 1K | |
| 02 | AK | Alaska | $157,991▼3% | $163,200 | 103.3 | 1K | |
| 03 | MN | Minnesota | $157,281▲2% | $154,610 | 98.3 | 6K | |
| 04 | OR | Oregon | $155,631▼5% | $163,120 | 104.8 | 4K | |
| 05 | AR | Arkansas | $154,625▲15% | $134,230 | 86.8 | 3K | |
| 06 | ND | North Dakota | $153,753▲13% | $135,570 | 88.2 | 1K | |
| 07 | MS | Mississippi | $152,572▲15% | $132,420 | 86.8 | 3K | |
| 08 | MO | Missouri | $151,376▲10% | $137,910 | 91.1 | 7K | |
| · · · · · 38 states omitted · · · · · | |||||||
| 47 | DC | District of Columbia | $127,862▼10% | $141,560 | 110.7 | 1K | |
| 48 | NY | New York | $126,435▼7% | $136,350 | 107.8 | 21K | |
| 49 | MA | Massachusetts | $126,334▼7% | $136,030 | 107.7 | 8K | |
| 50 | RI | Rhode Island | $125,420▼2% | $128,010 | 102.1 | 1K | |
| 51 | NJ | New Jersey | $121,635▼8% | $132,510 | 108.9 | 11K | |
| RPP source: BEA Regional Price Parities, 2023 release. P10–P90 from BLS OEWS May 2024. | Real P50 = Nominal P50 × (100 / RPP) | ||||||
Pharmacist Salary at a Glance (BLS OEWS public API v2, May 2024)
Pharmacists (BLS code 29-1051) sit at the intersection of healthcare, regulation, and retail logistics. 328,870 employed nationally, with the May 2024 OES release showing annual median wage of $137,480 and mean of $137,210. Middle 50% earn $127,250–$158,620; top 10% exceed $172,040.
The single SOC pools retail-chain pharmacists, hospital staff pharmacists, clinical specialists with PGY-1/PGY-2 residency, industry / pharma / PBM pharmacists, and pharmacy managers. The setting and credentialing differential is substantial: industry pharmacists at PBMs and pharma companies routinely earn 30–60% above retail-chain front-line.
| Percentile | Annual | Hourly |
|---|---|---|
| P10 | $86,930 | $41.79 |
| P25 | $127,250 | $61.18 |
| P50 (median) | $137,480 | $66.10 |
| P75 | $158,620 | $76.26 |
| P90 | $172,040 | $82.71 |
| Mean | $137,210 | $65.97 |
BLS OES 29-1051, May 2024 release. Last synced 2026-05-05. W-2 wages only — pharma / PBM bonuses, equity, and rural-undersupply sign-on bonuses ($20–50K common) are partially captured but not fully.
By Setting: Where the Same License Pays Differently
| Setting | Typical pay (2025–2026) | Trend | Key driver |
|---|---|---|---|
| Retail chain (CVS, Walgreens, Rite Aid) | $110–145K | Compressing | PBM consolidation + DIR fees + store closures |
| Independent / small chain retail | $110–140K | Stable, regional | Local demand; rural premium common |
| Hospital staff pharmacist | $125–165K | Stable | Strong benefits, pension; demand by region |
| Hospital clinical specialist (PGY-1) | $140–180K | Growing | BCPS / specialty boards |
| Clinical specialty (PGY-2: oncology, ID, ambulatory) | $160–200K | Growing | BCOP, BCACP, BCID |
| Industry / pharma / managed care / PBM | $150–250K + bonus | Growing | Medical affairs, formulary, MTM |
| Federal / VA Title-38 | $130–180K + pension | Stable | Loan-forgiveness path |
The pharmacist career has bifurcated since 2020. Retail-only paths face hour cuts, store closures, and offers below historical baseline in saturated metros. Clinical, hospital, industry, and PBM paths are stable-to-growing with strong premium credentials (BCPS / BCOP / BCACP / BCID). The strategic move for early-career PharmDs is to use staff retail roles to fund residency rather than treating retail as a destination.
By State: Real Take-Home After RPP Adjustment
West-coast metros and rural-undersupply states drive the top of nominal pay. After BEA Regional Price Parity (2023), the ranking shifts toward lower-RPP rural-premium states.
Top 5 — Nominal Median (P50)
| State | P50 | RPP | Real P50 |
|---|---|---|---|
| CA | $165,150 | 112.2 | $147,199 |
| AK | $163,200 | 103.3 | $157,991 |
| OR | $163,120 | 104.8 | $155,631 |
| WA | $157,020 | 108.4 | $144,892 |
| MN | $154,610 | 98.3 | $157,281 |
Top 5 — Real Take-Home (RPP-Adjusted)
| State | P50 | RPP | Real P50 |
|---|---|---|---|
| SD | $140,190 | 88.1 | $159,038 |
| AK | $163,200 | 103.3 | $157,991 |
| MN | $154,610 | 98.3 | $157,281 |
| OR | $163,120 | 104.8 | $155,631 |
| AR | $134,230 | 86.8 | $154,625 |
BLS OES 29-1051 state-level + BEA RPP 2023.
PharmD ROI in 2026: Has the Math Changed?
Yes — meaningfully. PharmD programs run $35–60K/year tuition × 4 years plus 4 years of foregone earnings, putting all-in cost over $200K for many students. With retail-chain pay compression in 2023–2025:
- Retail-only career: ROI breakeven now 12–18 years post-graduation in most markets — substantially worse than the pre-2020 baseline of 6–10 years.
- Hospital + PGY-1: 8–12 years to breakeven, with strong benefits / pension closing the lifetime gap further.
- Clinical specialist + PGY-2 + boards: 6–10 years to breakeven with much stronger lifetime trajectory.
- Industry / PBM / managed care: fastest payback, often 5–8 years; highest lifetime ceiling.
Compared to alternatives: NP and PA training (master's, $80–100K cost, $100–140K typical pay) often deliver better risk-adjusted ROI than PharmD for retail-pharmacy-only goals. MD requires substantially more time and cost but specialty pay ceiling is much higher. PharmD is now a credential that works best when paired with residency + boards or industry pivot, not as a standalone retail-pharmacy path.
Is the Pharmacist Market Oversupplied?
National PharmD output peaked around 2018 and has stayed above retiree-replacement rates. The result: bifurcated labor markets.
- Saturated metros (NY, CA, IL, FL coastal markets): chain hour cuts, sign-on bonuses below historical baseline, longer time-to-offer for new grads.
- Rural / underserved markets: $20–50K sign-on bonuses common, fast-tracked offers, sometimes housing assistance. The IHS / PHS Commissioned Corps / federal HRSA loan-forgiveness paths target these markets directly.
- Hospital + clinical with residency: not oversupplied; specialty boards (BCPS, BCOP, BCACP, BCID) are differentiators that consistently pull pay above the BLS median.
- Industry / PBM: not oversupplied; demand growing as managed-care and PBM consolidation continues.
Methodology & Data Sources
Wage data: BLS OES 29-1051 (Pharmacists), May 2024 release, fetched via the BLS OEWS public API v2, May 2024. State-level: BLS OES state files. Real-wage adjustment: BEA Regional Price Parities, BEA Regional Price Parities (SARPP), 2023. PharmD program tuition / placement: AACP. Specialty board credentials: Board of Pharmacy Specialties. PBM market structure: industry consolidation reports 2023–2025. Last synced: 2026-05-05. BLS does not segment retail / hospital / industry pharmacist pay; bands here are blended from industry surveys (ASHP, NACDS) and major-employer disclosures.
FAQ
- What is the national median pharmacist salary in 2026?
- Per BLS OES May 2024, the national annual median wage for Pharmacists (SOC 29-1051) is $137,480; the mean is $137,210. Middle 50% earn $127,250–$158,620; top 10% exceed $172,040. Total employment is 328,870 pharmacists nationally.
- Retail vs hospital vs clinical vs industry — which setting pays best?
- Retail chain (CVS, Walgreens, independents) historically led on starting pay but has compressed as chain consolidation, store closures, and 2023–2025 hour cuts squeeze margins. Hospital typically pays mid-band ($125–165K) with much stronger benefits and pension. Clinical specialty (oncology, infectious disease, ambulatory care) leads at the senior level — typically $140–195K with PGY-1/PGY-2 residency credentials. Industry / pharma / PBM / managed care sits at the high end ($150–250K + bonus + equity) and is the strongest single comp track for experienced pharmacists.
- Is the PharmD degree still worth $150–220K of tuition?
- PharmD programs run $35–60K/year tuition × 4 years plus 4 years of foregone earnings, putting all-in cost over $200K for many students. With the national median above and retail pay compression in 2023–2025, ROI breakeven is now 12–18 years post-graduation in retail-only careers — substantially worse than the pre-2020 baseline (when 6–10 years was typical). Hospital + clinical + industry tracks payback faster (8–12 years) thanks to higher senior pay and stronger benefits.
- How much do staff vs senior vs clinical pharmacists earn?
- Typical bands (national, 2025–2026): staff retail or hospital pharmacist $110–135K (yr 0–3); senior staff or pharmacist-in-charge $130–160K (yr 3–8); clinical specialist (with PGY-1) $140–180K (yr 3+); board-certified specialist (BCPS / BCOP / BCACP, with PGY-2) $160–200K; pharmacy manager / director $150–220K. Industry medical-affairs and PBM clinical roles run higher ($170–250K+ with bonus).
- Is there a pharmacist oversupply / labor surplus?
- Yes in saturated metros, no in rural markets. National PharmD output peaked around 2018 and has stayed above retiree replacement, contributing to chain-pharmacy hour cuts and below-baseline starting offers in NY, CA, IL, and other dense metros. Rural markets remain undersupplied — sign-on bonuses of $20–50K for rural retail or hospital roles are common in 2025–2026. Hospital and clinical roles requiring residency are not oversupplied; specialty boards (BCPS, BCOP, BCACP) are still strong differentiators.
- Where do pharmacists earn the most after cost-of-living?
- Nominal leaders are CA ($165,150), AK ($163,200), OR ($163,120) — typically west-coast metros (CA, OR, WA, AK) plus some lower-density rural-undersupply states. After BEA Regional Price Parities, the real-wage leaders are SD ($159,038), AK ($157,991), MN ($157,281).
- Is residency (PGY-1 / PGY-2) worth the year of half-pay?
- For pharmacists targeting hospital, clinical, or industry tracks: almost always yes. PGY-1 (1 year, ~$50–60K stipend vs $120K+ staff salary) is required for most hospital clinical roles and unlocks the BCPS path. PGY-2 (additional year of subspecialty training) opens oncology, infectious disease, critical care, and ambulatory care positions paying $30–70K above non-board-certified staff over a career. For retail-only careers, residency adds little. The 1–2 year opportunity cost typically pays back in 4–6 years post-residency.
- How are PBMs and managed care affecting pharmacist pay?
- PBM consolidation (CVS Caremark, Express Scripts/Cigna, OptumRx) and DIR-fee dynamics are the largest single pressure on retail-pharmacy economics — directly responsible for the chain hour cuts and store closures since 2023. For pharmacists working at PBMs (clinical pharmacy, formulary management, MTM, P&T committee work), pay is among the highest non-physician healthcare specialty roles ($150–250K+) and demand is growing. The bifurcation: bad for retail front-line, good for clinical-pharmacist-as-payer.
- Is pharmacy school a good choice in 2026 vs other healthcare paths?
- Compared to MD ($350K+ tuition, 7–11 years post-college, $250–600K specialty pay) or PA / NP (master's, $80–100K cost, $100–140K pay): PharmD sits awkwardly — high cost like medical training, lower ceiling than physician careers, in an oversupplied retail market. The strongest case for PharmD remains industry / managed-care / clinical specialty paths (with PGY-1/PGY-2 + boards), where pay rivals NP/PA and clinical autonomy is high. For retail-pharmacy-only goals, alternatives like PA or NP have stronger 2025–2030 ROI in most markets.
- Federal / VA / Public Health Service pharmacist pay?
- VA pharmacists run the GS scale, typically GS-12/13 with VA-specific Title-38 supplements pushing total comp to $130–180K range plus federal pension, which materially closes the gap with private-sector hospital pay. Indian Health Service and Public Health Service Commissioned Corps offer loan-forgiveness paths attractive to PharmDs with $200K+ student debt. Federal Bureau of Prisons pharmacists earn similarly. These paths trade lower nominal pay for stronger benefits and student-loan forgiveness.